









Markets
/
Stocks
/
nasdaq-axgn
/

AxoGen Inc

AXGN



View Detailed Chart

31.980USD

+0.280+0.88%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

1.47BMarket Cap

LossP/E TTM



AxoGen Inc

31.980

+0.280+0.88%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.88%

5 Days

+5.23%

1 Month

+26.60%

6 Months

+244.24%

Year to Date

+94.05%

1 Year

+115.35%

View Detailed Chart

TradingKey Stock Score of AxoGen Inc

Currency: USD Updated: 2025-12-19

Key Insights

AxoGen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 5/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.20.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AxoGen Inc's Score

Industry at a Glance

Industry Ranking

5 / 208

Overall Ranking

48 / 4582

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

35.200

Target Price

+14.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

AxoGen Inc Highlights

StrengthsRisks

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.18% year-on-year.

Undervalued

The company’s latest PE is -764.71, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 42.08M shares, increasing 0.02% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.29K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.01.